Viewing data from:

VUSION

NDA

MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE | N021026 | MYLAN PHARMACEUTICALS INC

1 strength1 unique patent0 unique exclusivities

Patent Timeline

1 unique patent by expiration date

Active (1)Today

2027

2028

Today

8147852

Mar. 30, 2028

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$9.12

per gm

Lowest NADAC/Unit

$9.12

per gm

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00378822250MICONAZOLE-ZINC-PETRO 0.25-15%	$9.12	GM	Generic	—	2026-01-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 4 NDCs (2 FSS, 2 Big4)

Lowest Price

$172.05

Highest Price

$556.91

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00378-9730-50VUSION 0.25%/15% OINTMENT	$556.91	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-9730-50VUSION 0.25%/15% OINTMENT	$428.32	Big4	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-8222-50MICONAZOLE NITRATE 0.25%/ZINC OXIDE 15% OINT,	$409.81	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-8222-50MICONAZOLE NITRATE 0.25%/ZINC OXIDE 15% OINT,	$172.05	Big4	Mylan Pharmaceuticals, Inc.	12/31/2027

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Vusion (2024)

Total Spending

$31K

Total Claims

Beneficiaries

Avg Cost/Unit

$11.10

Spending Trend

$18K(2020)→$59K(2021)→$49K(2022)→$35K(2023)→$31K(2024)

YoY Change:-4.6%

5yr CAGR:-0.3%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Approval Letters

3 letters from Drugs@FDA

Date	Submission	Document
Apr 2, 2010	SUPPL -6	View Letter (PDF)
Oct 4, 2007	SUPPL -4	View Letter (PDF)
Mar 1, 2006	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.25%;81.35%;15%

RLD

1 patent0 exclusivities▴

OINTMENT;TOPICAL | Approved: Feb 16, 2006

Patents (1) · 1 use code

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8147852	Mar 30, 2028	—	—	—		—